Diazoxide reduces status epilepticus neuron damage in diabetes

Neurotox Res. 2010 May;17(4):305-16. doi: 10.1007/s12640-009-9104-3. Epub 2009 Sep 1.

Abstract

Diabetic hyperglycemia is associated with seizure severity and may aggravate brain damage after status epilepticus. Our earlier studies suggest the involvement of ATP-sensitive potassium channels (K(ATP)) in glucose-related neuroexcitability. We aimed to determine whether K(ATP) agonist protects against status epilepticus-induced brain damage. Adult male Sprague-Dawley rats were divided into two groups: the streptozotocin (STZ)-induced diabetes (STZ) group and the normal saline (NS) group. Both groups were treated with either diazoxide (15 mg/kg, i.v.) (STZ + DZX, NS + DZX) or vehicle (STZ + V, NS + V) before lithium-pilocarpine-induced status epilepticus. We evaluated seizure susceptibility, severity, and mortality. The rats underwent Morris water-maze tests and hippocampal histopathology analyses 24 h post-status epilepticus. A multi-electrode recording system was used to study field excitatory postsynaptic synaptic potentials (fEPSP). RNA interference (RNAi) to knockdown Kir 6.2 in a hippocampal cell line was used to evaluate the effect of diazoxide in the presence of high concentration of ATP. Seizures were less severe (P < 0.01), post-status epilepticus learning and memory were better (P < 0.05), and neuron loss in the hippocampal CA3 area was lower (P < 0.05) in the STZ + DZX than the STZ + V group. In contrast, seizure severity, post-status epilepticus learning and memory, and hippocampal CA3 neuron loss were comparable in the NS + DZX and NS + V groups. fEPSP was lower in the STZ + DZX but not in the NS + DZX group. The RNAi study confirmed that diazoxide, with its K(ATP)-opening effects, could counteract the K(ATP)-closing effect by high dose ATP. We conclude that, by opening K(ATP), diazoxide protects against status epilepticus-induced neuron damage during diabetic hyperglycemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / pharmacology
  • Analysis of Variance
  • Animals
  • Blood Glucose / drug effects
  • Cell Line, Transformed
  • Diabetes Mellitus, Experimental / complications
  • Diazoxide / pharmacology
  • Diazoxide / therapeutic use*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Excitatory Postsynaptic Potentials / drug effects
  • Excitatory Postsynaptic Potentials / physiology
  • Gene Expression Regulation / drug effects
  • Hippocampus / pathology
  • In Situ Nick-End Labeling / methods
  • In Vitro Techniques
  • Lithium Chloride
  • Male
  • Maze Learning / drug effects
  • Neurons / drug effects*
  • Patch-Clamp Techniques
  • Potassium Channels, Inwardly Rectifying / genetics
  • Potassium Channels, Inwardly Rectifying / metabolism
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Status Epilepticus / chemically induced
  • Status Epilepticus / drug therapy*
  • Status Epilepticus / pathology*
  • Transfection / methods
  • Vasodilator Agents / pharmacology
  • Vasodilator Agents / therapeutic use*

Substances

  • Blood Glucose
  • Kir6.2 channel
  • Potassium Channels, Inwardly Rectifying
  • RNA, Small Interfering
  • Vasodilator Agents
  • Adenosine Triphosphate
  • Lithium Chloride
  • Diazoxide